NEWS | BEAM Alliance


Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Allschwil, Switzerland, September 28, 2023

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine (NEJM), one of the world’s leading peer-reviewed medical journals. In the study, Basilea’s ceftobiprole, a beta-lactam antibiotic, was evaluated for the treatment of bacterial bloodstream infections caused by Staphylococcus aureus in adult patients, also known as Staphylococcus aureus bacteremia (SAB). ERADICATE is the largest registrational study for SAB conducted to date and ceftobiprole showed similar clinical benefit compared to daptomycin, which is a standard of care antibiotic in the treatment of SAB.

ERADICATE was a double-blind, non-inferiority study, which included 390 adult patients with complicated SAB, including right-sided infective endocarditis, at 60 sites in 17 countries.2 Patients were randomized to receive infusions of ceftobiprole or daptomycin (plus optional aztreonam) for up to 42 days.

The primary outcome of the study was overall treatment success at 70 days after randomization defined by survival, bacteremia clearance, symptom improvement, no new SAB-related complications, and no receipt of other potentially effective antibiotics.

Using a pre-defined non-inferiority margin of 15%, treatment with ceftobiprole was non-inferior to daptomycin with overall treatment success achieved in 69.8% of patients in the ceftobiprole group compared to 68.7% in the daptomycin group.

The results for the primary study outcome were consistent in key subgroups, including patients with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA). Clearance of MRSA bacteria from the bloodstream was achieved in 93.3% of patients in the ceftobiprole group compared with 87.8% in the daptomycin group after a median of 5 days of treatment, and clearance of MSSA bacteria from the bloodstream was achieved in 94.3% of patients in the ceftobiprole group after a median of 3 days of treatment compared with 95.2% in the daptomycin group after a median of 4 days of treatment.

Ceftobiprole was generally well tolerated and showed a safety profile consistent with previous phase 3 studies and the post-marketing experience. The overall percentage of patients reporting adverse events was similar between the two treatment groups with more patients reporting gastrointestinal adverse events in the ceftobiprole group, typical for the beta-lactam class of antibiotics. There were no reports of Clostridioides difficile infections in either group.

Thomas Holland, M.D., Associate Professor in the department of Medicine at Duke University School of Medicine and chair of the data review committee of the study, said: “This is an area with a high need to provide new treatments to patients and there has not been a new antibiotic approved for the treatment of Staphylococcus aureus bacteremia for over 15 years.” Vance G. Fowler, Jr., M.D., Professor in the departments of Medicine and Molecular Genetics & Microbiology at Duke University School of Medicine and academic lead investigator, added: “Complicated Staphylococcus aureus infections have a high mortality rate and are associated with substantial morbidity and we need more options for treating these infections, especially if MRSA is involved.”

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data from the ERADICATE study published in the NEJM support the potent activity of ceftobiprole for treating serious bacterial infections. Based on ERADICATE and additional randomized controlled phase 3 studies, we have recently submitted a New Drug Application to the US Food and Drug Administration, seeking approval of ceftobiprole for treating patients in three indications: Staphylococcus aureus bacteremia, including right-sided infective endocarditis, acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.”

Basilea’s ceftobiprole phase 3 program is funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the phase 3 studies in SAB and acute bacterial skin and skin structure infections (ABSSSI), regulatory activities and nonclinical work.

Full PR available here